NewAmsterdam Phar…
USUSDNewAmsterdam Pharma Company N.V. (US:NAMS) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 1. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- ir.newamsterdampharma.com
- Settore
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Centrale
- NARRDEN, Netherlands
- Amministratore Delegato
- Michael Harvey Davidson
- Dipendenti
- 100
- Azioni in Circolazione
- 119.54 Mln al 2026-08-03
- Flottante
- 81.5 Mln
- Capitalizzazione di Mercato
- 2.89 Mld USD
- Insider
- 0.9%
- Investitori Istituzionali
- 106.61%
- Settore (SIC)
- Pharmaceutical Preparations
- P/E
- perdita
- FCF
- −144 Mln USD
- Debito
- ?
- Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Borse e Ticker
| Borsa | Ticker | Valuta | Prezzo | Tipo |
|---|---|---|---|---|
| US USA Stocks | NAMS | USD | 21.25 -1.51% | azioni ordinarie |
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Frazier Life Sciences Ma… | 15.13% | 18.09 Mln | 2026-06-30 |
| Capital World Investors | 10.23% | 12.23 Mln | 2026-06-30 |
| FMR, LLC | 8.65% | 10.34 Mln | 2026-06-30 |
| RA Capital Management, L… | 7.99% | 9.55 Mln | 2026-06-30 |
| SmallCap World Fund Inc | 7.75% | 9.27 Mln | 2026-06-30 |
| FCPM III Services B.V. | 7.1% | 8.49 Mln | 2026-06-30 |
| Deerfield Management Com… | 3.57% | 4.26 Mln | 2026-06-30 |
| Viking Global Investors,… | 3.52% | 4.2 Mln | 2026-06-30 |
| Bain Capital Life Scienc… | 3.18% | 3.81 Mln | 2026-06-30 |
| Maverick Capital Ltd. | 2.73% | 3.27 Mln | 2026-06-30 |
| Duquesne Family Office L… | 2.57% | 3.07 Mln | 2026-06-30 |
| Fidelity Contrafund | 1.95% | 2.33 Mln | 2026-07-31 |
| Fidelity Rutland Square… | 1.87% | 2.24 Mln | 2026-07-31 |
| DAVIDSON MICHAEL H (Chie… | ≈0.9% | 1.08 Mln | 2026-09-14 |
| New Economy Fund | 0.8% | 957 477 | 2026-06-30 |
| T. Rowe Price Health Sci… | 0.76% | 912 500 | 2026-06-30 |
| Fidelity Select Portfoli… | 0.71% | 847 600 | 2026-07-31 |
| -Capital Group U.S. Smal… | 0.51% | 608 660 | 2026-05-31 |
| iShares Trust-iShares Bi… | 0.5% | 603 124 | 2026-08-31 |
| Prudential Sector Funds,… | 0.45% | 534 102 | 2026-05-31 |
| American Century Mutual… | 0.44% | 524 241 | 2026-07-31 |
| SOMAIYA MAYUR IAN (Chief… | ≈0.05% | 58 382 | 2026-01-21 |
| MARINO MICHAEL F III (Of… | ≈0.05% | 55 000 | 2025-05-30 |
| KLING DOUGLAS F (Chief O… | ≈0.04% | 44 000 | 2025-07-16 |
| JONES WILLIAM A JR (Offi… | ≈0.04% | 43 000 | 2025-01-07 |
| KOOIJ LOUISE FREDERIKA (… | ≈0.02% | 24 353 | 2026-07-20 |
| AUDET JULIETTE BERANGERE… | ≈0.01% | 15 104 | 2025-01-07 |
| FORGROWTH NAP B.V. (Bene… | — | — | 2024-12-30 |
| KASTELEIN JOHANNES JACOB… | — | — | 2026-08-24 |
| TOPPER JAMES N (Director… | — | — | 2025-09-15 |
Accedi con Google